These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma. Proctor AE; Thompson LA; O'Bryant CL Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609 [TBL] [Abstract][Full Text] [Related]
4. Targeting the hedgehog pathway to treat basal cell carcinoma. Geeraert P; Williams JS; Brownell I J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945 [TBL] [Abstract][Full Text] [Related]
5. Discovery and preclinical development of vismodegib. Gould SE; Low JA; Marsters JC; Robarge K; Rubin LL; de Sauvage FJ; Sutherlin DP; Wong H; Yauch RL Expert Opin Drug Discov; 2014 Aug; 9(8):969-84. PubMed ID: 24857041 [TBL] [Abstract][Full Text] [Related]
6. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma. Cirrone F; Harris CS Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338 [TBL] [Abstract][Full Text] [Related]
7. Hedgehog Pathway Inhibition. Sekulic A; Von Hoff D Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418 [TBL] [Abstract][Full Text] [Related]
8. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279 [TBL] [Abstract][Full Text] [Related]
9. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma. Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490 [TBL] [Abstract][Full Text] [Related]
10. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449). Meani RE; Lim SW; Chang AL; Kelly JW Australas J Dermatol; 2014 Aug; 55(3):218-21. PubMed ID: 25117162 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinoma. Lyons TG; O'Kane GM; Kelly CM Expert Opin Drug Saf; 2014 Aug; 13(8):1125-32. PubMed ID: 25033383 [TBL] [Abstract][Full Text] [Related]
12. Vismodegib: a hedgehog pathway inhibitor for locally advanced and metastatic basal cell carcinomas. Sobanko JF; Okman J; Miller C J Drugs Dermatol; 2013 Oct; 12(10 Suppl):s154-5. PubMed ID: 24085062 [TBL] [Abstract][Full Text] [Related]
13. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma. Lyseng-Williamson KA; Keating GM Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081 [TBL] [Abstract][Full Text] [Related]
14. Vismodegib: the first drug approved for advanced and metastatic basal cell carcinoma. Dubey AK; Dubey S; Handu SS; Qazi MA J Postgrad Med; 2013; 59(1):48-50. PubMed ID: 23525058 [TBL] [Abstract][Full Text] [Related]
15. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial. Dessinioti C; Plaka M; Stratigos AJ Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979 [TBL] [Abstract][Full Text] [Related]
16. Vismodegib: a review. Ruiz-Salas V; Alegre M; López-Ferrer A; Garcés JR Actas Dermosifiliogr; 2014 Oct; 105(8):744-51. PubMed ID: 24359667 [TBL] [Abstract][Full Text] [Related]
17. Vismodegib in the treatment of advanced BCC. O'Kane GM; Lyons T; McDonald I; Mulligan N; Moloney FJ; Murray D; Kelly CM Ir Med J; 2014; 107(7):215-6. PubMed ID: 25226719 [TBL] [Abstract][Full Text] [Related]
18. Hedgehog signaling pathway and cancer therapeutics: progress to date. Ruch JM; Kim EJ Drugs; 2013 May; 73(7):613-23. PubMed ID: 23605693 [TBL] [Abstract][Full Text] [Related]
19. Vismodegib (Erivedge) for basal cell carcinoma. Med Lett Drugs Ther; 2012 Jul; 54(1394):53-4. PubMed ID: 22777303 [No Abstract] [Full Text] [Related]
20. Locally advanced and metastatic basal cell carcinoma: molecular pathways, treatment options and new targeted therapies. Ruiz Salas V; Alegre M; Garcés JR; Puig L Expert Rev Anticancer Ther; 2014 Jun; 14(6):741-9. PubMed ID: 24611655 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]